Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.

BACK TO LIST

Patient
Name:	Green, Elaine
DOB:	05-AUG-1942 (Age: 83)
Gender:	female
Address:	Studio 30N Maurice lakes M1 East Georginastad (United Kingdom)
ID:	9467-500577-4 (ECI)

Report
Date:	19-NOV-2020

Laboratory
dr Ample, Ex Laboratoire Central Européenne Boulevard du Jardin Botanique 32 1000 Brussels (Belgium)

Requested by
Cornbrook Medical Practice City Road 204 M3 3 Manchester (United Kingdom)

Specimen
Collected:	19-NOV-2020

Hematology

Test	19-NOV-2020	Reference Range	Unit
Leukocytes [#/volume] in Blood by Automated count	9.6	4.0 - 11.0	10*3/uL
Erythrocytes [#/volume] in Blood by Automated count	5.0	3.8 - 5.2	10*6/uL
Hemoglobin [Mass/volume] in Blood	14.0	12 - 16	g/dL
Hematocrit [Volume Fraction] of Blood by Automated count	41.9	36 - 46	%
MCV [Entitic mean volume] in Red Blood Cells by Automated count	80.7	80 - 100	fL
MCH [Entitic mass] by Automated count	32.7	27 - 33	pg
MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count	33.4	32 - 36	g/dL
Erythrocyte distribution width [Entitic volume] by Automated count	43.9	36 - 48	fL
Platelets [#/volume] in Blood by Automated count	392.5	150 - 450	10*3/uL
Platelet distribution width [Entitic volume] in Blood by Automated count	383.0 H	9.4 - 15.9	fL
Platelet [Entitic mean volume] in Blood by Automated count	10.5	7.2 - 11.5	fL

Chemistry

Test	19-NOV-2020	Reference Range	Unit
Hemoglobin A1c/Hemoglobin.total in Blood	6.2 H	4.8 - 5.6	%
Glucose [Mass/volume] in Blood	77.5	70 - 100	mg/dL
Urea nitrogen [Mass/volume] in Blood	17.1	7 - 20	mg/dL
Creatinine [Mass/volume] in Blood	0.6	0.6 - 1.3	mg/dL
Calcium [Mass/volume] in Blood	8.9	8.5 - 10.5	mg/dL
Sodium [Moles/volume] in Blood	137.0	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	4.5	3.5 - 5.1	mmol/L
Chloride [Moles/volume] in Blood	103.1	98 - 107	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	27.4	22 - 29	mmol/L
Cholesterol [Mass/volume] in Serum or Plasma	185.6	125 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	149.3 H	0 - 149	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	96.2	0 - 100	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	59.6	40 - 90	mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine	16.9	0 - 30	mg/g

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows mildly elevated HbA1c, indicating impaired glucose metabolism or possible prediabetes, and borderline high triglycerides, suggesting increased cardiovascular risk. All other parameters, including renal function, electrolytes, blood count, and urine microalbumin, are within normal limits. The high platelet distribution width may reflect platelet activation but is of unclear clinical significance without further context. Overall, results are largely unremarkable except for mild dysglycemia and hypertriglyceridemia; recommend clinical correlation and monitoring of metabolic parameters.

Conclusion and Recommendations based on this report and previous findings known to us

The patient shows mildly elevated HbA1c, indicating impaired glucose metabolism or possible prediabetes, and borderline high triglycerides, suggesting increased cardiovascular risk. All other parameters, including renal function, electrolytes, blood count, and urine microalbumin, are within normal limits. The high platelet distribution width may reflect platelet activation but is of unclear clinical significance without further context. Overall, results are largely unremarkable except for mild dysglycemia and hypertriglyceridemia; recommend clinical correlation and monitoring of metabolic parameters.